These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors. Mony L; Krzaczkowski L; Leonetti M; Le Goff A; Alarcon K; Neyton J; Bertrand HO; Acher F; Paoletti P Mol Pharmacol; 2009 Jan; 75(1):60-74. PubMed ID: 18923063 [TBL] [Abstract][Full Text] [Related]
26. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846 [TBL] [Abstract][Full Text] [Related]
27. Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping. Hall A; Billinton A; Brown SH; Chowdhury A; Giblin GM; Goldsmith P; Hurst DN; Naylor A; Patel S; Scoccitti T; Theobald PJ Bioorg Med Chem Lett; 2008 Apr; 18(8):2684-90. PubMed ID: 18378447 [TBL] [Abstract][Full Text] [Related]
28. The novel NMDA receptor antagonist, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, is a gating modifier in cultured mouse cortical neurons. Noh J; Lee ES; Chung JM J Neurochem; 2009 Jun; 109(5):1261-71. PubMed ID: 19302475 [TBL] [Abstract][Full Text] [Related]
29. Computational studies to discover a new NR2B/NMDA receptor antagonist and evaluation of pharmacological profile. Gitto R; De Luca L; Ferro S; Occhiuto F; Samperi S; De Sarro G; Russo E; Ciranna L; Costa L; Chimirri A ChemMedChem; 2008 Oct; 3(10):1539-48. PubMed ID: 18767069 [TBL] [Abstract][Full Text] [Related]
30. Functional in vitro characterization of CR 3394: a novel voltage dependent N-methyl-D-aspartate (NMDA) receptor antagonist. Losi G; Lanza M; Makovec F; Artusi R; Caselli G; Puia G Neuropharmacology; 2006 Mar; 50(3):277-85. PubMed ID: 16236334 [TBL] [Abstract][Full Text] [Related]
31. Brain-derived neurotrophic factor acutely enhances tyrosine phosphorylation of the AMPA receptor subunit GluR1 via NMDA receptor-dependent mechanisms. Wu K; Len GW; McAuliffe G; Ma C; Tai JP; Xu F; Black IB Brain Res Mol Brain Res; 2004 Nov; 130(1-2):178-86. PubMed ID: 15519688 [TBL] [Abstract][Full Text] [Related]
32. An antisense oligonucleotide to the N-methyl-D-aspartate (NMDA) subunit NMDAR1 attenuates NMDA-induced nociception, hyperalgesia, and morphine tolerance. Shimoyama N; Shimoyama M; Davis AM; Monaghan DT; Inturrisi CE J Pharmacol Exp Ther; 2005 Feb; 312(2):834-40. PubMed ID: 15388787 [TBL] [Abstract][Full Text] [Related]
33. Late phase of long-term potentiation induced by co-application of N-methyl-d-aspartic acid and the antagonist of NR2B-containing N-methyl-d-aspartic acid receptors in rat hippocampus. Oh-Nishi A; Saji M; Satoh SZ; Ogata M; Suzuki N Neuroscience; 2009 Mar; 159(1):127-35. PubMed ID: 19010396 [TBL] [Abstract][Full Text] [Related]
34. Long-term potentiation in the nucleus accumbens requires both NR2A- and NR2B-containing N-methyl-D-aspartate receptors. Schotanus SM; Chergui K Eur J Neurosci; 2008 Apr; 27(8):1957-64. PubMed ID: 18412616 [TBL] [Abstract][Full Text] [Related]